Clinical trial
Busulfan in Treating Children and Adolescents With Refractory CNS Cancer
NCT00006246 · Pediatric Brain Tumor Consortium, Other · Completed
Key facts
| NCT number | NCT00006246 |
|---|---|
| Title | Busulfan in Treating Children and Adolescents With Refractory CNS Cancer |
| Official title | Phase I Study of Intrathecal Spartaject-Busulfan in Children With Neoplastic Meningitis |
| Lead sponsor | Pediatric Brain Tumor Consortium, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Brain and Central Nervous System Tumors, Childhood Germ Cell Tumor, Leukemia, Lymphoma, Metastatic Cancer, Retinoblastoma, Sarcoma |
| Intervention type | Drug |
| Interventions | busulfan |
| Enrollment | 28 |
| Start date | Nov 1, 2000 |
| Primary completion | May 1, 2003 |
| First posted | Jan 27, 2003 |
| Last update posted | Oct 7, 2009 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: